Trial Profile

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients With Relapsed/Refractory Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iparomlimab/tuvonralimab (Primary)
Indications Colon cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Renal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Sound Biologics

07 Jun 2022 Safety data presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
23 Nov 2020 Planned End Date changed from 1 Jul 2021 to 28 Jul 2021.
23 Nov 2020 Planned primary completion date changed from 1 Feb 2021 to 28 Feb 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com